Physician profile
John Collins
NPI 1588764369
$1,270.15
in general payments reported to CMS, 2019-2025
27 companies · $74.81 in 2025
The $74.81 reported for 2025 was less than what a typical Neurological Surgery provider received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $31.52 · 2021: $248 · 2022: $475 · 2023: $264 · 2024: $177 · 2025: $74.81.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $515.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $515.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuropace, INC. | $287.06 | 2022 | |
| Livanova USA, INC. | $189.79 | 2021-2022 | |
| Integra Lifesciences Corporation | $177.83 | 2021-2024 | Codman Certas, Cusa Clarity, Duraseal Exact Spinal Sealant System |
| Neurelis, INC. | $59.38 | 2022-2023 | Valtoco |
| Ucb, INC. | $57.61 | 2024 | Briviact |
| Depuy Synthes Sales INC. | $42.63 | 2022 | |
| Karl Storz Endoscopy-America | $37.04 | 2023 | |
| Azurity Pharmaceuticals, INC. | $34.94 | 2024-2025 | Zonisade |
| Alexion Pharmaceuticals, INC. | $34.18 | 2023 | Koselugo |
| Arkis Biosciences INC | $31.52 | 2020 | |
| Immedica Pharma US, INC. | $28.06 | 2023-2024 | |
| Medtronic, INC. | $24.88 | 2023 | Synchromedii |
| Intrabio INC | $22.58 | 2025 | Aqneursa |
| Phadia US INC. | $21.75 | 2024 | Immunocap |
| Ultragenyx Pharmaceutical INC. | $20.45 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Itf Therapeutics LLC | $19.50 | 2024 | |
| Biomarin Pharmaceutical INC. | $19.40 | 2021 | |
| Mimedx Group, INC. | $19.19 | 2025 | |
| Aquestive Therapeutics, INC. | $17.79 | 2022 | |
| Travere Therapeutics, INC. | $17.35 | 2023 | Cholbam |
| Takeda Pharmaceuticals U.S.A., INC. | $17.09 | 2023 | Elaprase |
| Neurocrine Biosciences, INC. | $15.83 | 2025 | |
| Corium, LLC | $15.65 | 2022 | |
| Metacel Pharmaceuticals LLC | $15.10 | 2022 | |
| Tris Pharma INC | $14.81 | 2022 | |
| Ptc Therapeutics, INC. | $14.62 | 2022 | |
| Bioventus LLC | $14.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Collins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.